Your Article Summary
See Latest ArticlesBioMimetic Therapeutics, Inc. Announces Launch of Rights Offering
BioMimetic Therapeutics, 06/05/09
BioMimetic Therapeutics, Inc. announced that the Securities and Exchange Commission has declared effective the Registration Statement on Form S-3 filed by the Company in connection with the rights offering previously announced by the Company. Accordingly, the Company has launched the $17 million rights offering pursuant to which holders of its common stock, except with respect to shares of common stock held by the BioMimetic 401K Plan, will be entitled to purchase additional shares of its common stock at a price of $8.50 per share. T
Today in Medical Devices/Products...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Advisory Committee Supports Use of Aztreonam for Inhalation Solution for Patients with Cystic Fibrosis
Gilead, 12/14/09
Greater chances of cure for patients with HER2-positive early breast cancer when treated with one year of Herceptin
Roche, 12/14/09
Sanofi-aventis doubles syringe production capacity and diversifies vaccine production at the Le Trait Manufacturing Plant
Sanofi-aventis, 12/14/09